Key facts
| Recalling firm | Boston Scientific Corporation |
|---|---|
| Manufacturer | Not disclosed in the FDA record. |
| Brand name | Not disclosed in the FDA record. |
| Product description | Boston Scientific AVVIGO+ Multi-Modality Guidance System, AVVIGO + INT SYSTEM - ZERO COST JAPAN; the system utilizes an interactive display to provide physicians with physiologic, intravascular and/or intracardiac anatomical information. The system can provide various modalities which includes intravascular ultrasound (IVUS). When used with a peripheral vascular imaging catheter, the system utilizes the IVUS modality for ultrasound examination of intravascular pathology. |
| Classification | Class II |
| Recall number | Z-0096-2025 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | Boston Scientific has received reports indicating the grid mark overlay on the cross-sectional view did not present correctly when an OptiCross 18 Peripheral Imaging Catheter was connected to the AVVIGO+ Multi-Modality Guidance System while in either Live or Record mode. The Boston Scientific investigation determined that, due to a software anomaly, a 9-grid mark overlay is incorrectly displayed during Live mode when AVVIGO+ is connected to an OptiCross 18 Peripheral Imaging Catheter. Note that the correct overlay display for this catheter is the 15-grid mark overlay, which allows for a reference depth setting of 14.9mm for peripheral catheters. This software anomaly is limited to Live or Record mode. In Review mode, the correct 15-grid mark overlay is displayed, and the vessel image is correctly scaled to the appropriate size. |
What this classification means
A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Boston Scientific AVVIGO+ Multi-Modality Guidance System, AVVIGO + INT SYSTEM - ZERO COST JAPAN; the system utilizes an interactive display to provide physicians with physiologic, intravascular and/or intracardiac anatomical information. The system can provide various modalities which includes intravascular ultrasound (IVUS). When used with a peripheral vascular imaging catheter, the system utilizes the IVUS modality for ultrasound examination of intravascular pathology. should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Boston Scientific Corporation. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Boston Scientific Corporation should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Boston Scientific Corporation directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
Boston Scientific Corporation’s FDA history
Argus HQ has recorded 272 total FDA actions tied to Boston Scientific Corporation: 0 warning letters, 272 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- What is the recall class for Boston Scientific Corporation's recall?
- FDA classified this recall as Class II. A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
- Why was Boston Scientific AVVIGO+ Multi-Modality Guidance System, AV recalled?
- FDA's recall record states the reason as: Boston Scientific has received reports indicating the grid mark overlay on the cross-sectional view did not present correctly when an OptiCross 18 Peripheral Imaging Catheter was connected to the AVVIGO+ Multi-Modality Guidance System while in either Live or Record mode. The Boston Scientific investigation determined that, due to a software anomaly, a 9-grid mark overlay is incorrectly displayed during Live mode when AVVIGO+ is connected to an OptiCross 18 Peripheral Imaging Catheter. Note that the correct overlay display for this catheter is the 15-grid mark overlay, which allows for a reference depth setting of 14.9mm for peripheral catheters. This software anomaly is limited to Live or Record mode. In Review mode, the correct 15-grid mark overlay is displayed, and the vessel image is correctly scaled to the appropriate size.
- Who should I contact about this recall?
- Contact Boston Scientific Corporation directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.
- Has Boston Scientific Corporation had other FDA recalls or enforcement actions?
- Yes. Argus HQ has recorded 272 total FDA actions tied to Boston Scientific Corporation, including 272 recalls and 0 warning letters.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Boston Scientific Corporation- Recall: Boston Scientific Corporation — Class II recall: CRE Pro Wireguided 8-10mm 240cm →
- Recall: Boston Scientific Corporation — Class II recall: CRE Wireguided 15-18mm 240cm →
- Recall: Boston Scientific Corporation — Class II recall: CRE Wireguided 10-12mm 240cm →
- Recall: Boston Scientific Corporation — Class II recall: CRE Pro Wireguided 6-8mm 240cm →
- Recall: Boston Scientific Corporation — Class II recall: CRE Wireguided 6-8mm 240cm →
- Recall: Boston Scientific Corporation — Class II recall: CRE Wireguided 18-20mm 240cm →
- Recall: Boston Scientific Corporation — Class II recall: CRE Pro Wireguided 15-18mm 240cm →
- Recall: Boston Scientific Corporation — Class II recall: CRE Pro Wireguided 12-15mm 240cm →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2024). FDA Class II Recall: Boston Scientific AVVIGO+ Multi-Modality Guidance System, AVVIGO +… by Boston Scientific Corporation — Recall Details. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/boston-scientific-corporation-z-0096-2025-2024-10-23
"FDA Class II Recall: Boston Scientific AVVIGO+ Multi-Modality Guidance System, AVVIGO +… by Boston Scientific Corporation — Recall Details." Argus HQ Research, Digital Empire Holdings LLC, 2024, argushq.ai/recall/boston-scientific-corporation-z-0096-2025-2024-10-23.
Argus HQ Research. "FDA Class II Recall: Boston Scientific AVVIGO+ Multi-Modality Guidance System, AVVIGO +… by Boston Scientific Corporation — Recall Details." Digital Empire Holdings LLC. Accessed July 24, 2026. https://argushq.ai/recall/boston-scientific-corporation-z-0096-2025-2024-10-23.
@misc{argushq_argushq_ai_recall_boston_scientific_corporation_z_0096_2025_2024_10_23_2024,
title = {FDA Class II Recall: Boston Scientific AVVIGO+ Multi-Modality Guidance System, AVVIGO +… by Boston Scientific Corporation — Recall Details},
author = {{Argus HQ Research}},
year = {2024},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/boston-scientific-corporation-z-0096-2025-2024-10-23},
note = {Accessed: July 24, 2026}
}Source: FDA.gov — Recalls ↗

